Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Iscience|February 10, 2025
Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencingMingyang Ma, Chang Liu, Lei Jiang, et al.
Clinical and Translational Medicine|September 8, 2020
Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patientsZuhua Chen, Yingying Xu, Jifang Gong, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2023
Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacyKeren Jia, Yang Chen, Yi Xie, et al.
JCO Oncology Practice|January 14, 2025
Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled TrialLili Song, Ying Pang, Yi He, et al.
Clinical and Translational Science|February 12, 2025
The Role and Challenges of Investigator-Initiated Trials in the Cell and Gene Therapy Products Boom in Mainland ChinaYifan Yang, Lianlian Bian, Yuan Cheng, et al.
BMC Medicine|July 10, 2022
Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancerKeren Jia, Yang Chen, Yu Sun, et al.
British Journal of Cancer|November 29, 2025
Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancerJiarui Li, Lian Liu, Min Tao, et al.
JAMA Network Open|March 29, 2022
Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal CancerNa Zhuo, Chang Liu, Qi Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 17, 2019
Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular featuresYakun Wang, Li Sun, Zhongwu Li, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancerZhenghang Wang, Qi Zhang, Changsong Qi, et al.
Pageof 10